BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20372847)

  • 1. Identification of beta2-microgloblin as a candidate for early diagnosis of imaging-invisible hepatocellular carcinoma in patient with liver cirrhosis.
    Saito Y; Oba N; Nishinakagawa S; Mizuguchi Y; Kojima T; Nomura K; Nakatsura T
    Oncol Rep; 2010 May; 23(5):1325-30. PubMed ID: 20372847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of glypican-3-specific CTLs in chronic hepatitis and liver cirrhosis.
    Hayashi E; Motomura Y; Shirakawa H; Yoshikawa T; Oba N; Nishinakagawa S; Mizuguchi Y; Kojima T; Nomura K; Nakatsura T
    Oncol Rep; 2009 Jul; 22(1):149-54. PubMed ID: 19513517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma lipidomic fingerprinting to distinguish among hepatitis C-related hepatocellular carcinoma, liver cirrhosis, and chronic hepatitis C using MALDI-TOF mass spectrometry: a pilot study.
    Passos-Castilho AM; Lo Turco E; Ferraz ML; Matos C; Silva I; Parise E; Pilau E; Gozzo F; Granato C
    J Gastrointestin Liver Dis; 2015 Mar; 24(1):43-9. PubMed ID: 25822433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surface enhanced laser desorption/ionization profiling: New diagnostic method of HBV-related hepatocellular carcinoma.
    Wu C; Wang Z; Liu L; Zhao P; Wang W; Yao D; Shi B; Lu J; Liao P; Yang Y; Zhu L
    J Gastroenterol Hepatol; 2009 Jan; 24(1):55-62. PubMed ID: 18823443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of chronic hepatitis B, liver cirrhosis and hepatocellular carcinoma by SELDI-based serum decision tree classification.
    Cui J; Kang X; Dai Z; Huang C; Zhou H; Guo K; Li Y; Zhang Y; Sun R; Chen J; Li Y; Tang Z; Uemura T; Liu Y
    J Cancer Res Clin Oncol; 2007 Nov; 133(11):825-34. PubMed ID: 17516088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples.
    Göbel T; Vorderwülbecke S; Hauck K; Fey H; Häussinger D; Erhardt A
    World J Gastroenterol; 2006 Dec; 12(47):7604-12. PubMed ID: 17171788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease.
    Zinkin NT; Grall F; Bhaskar K; Otu HH; Spentzos D; Kalmowitz B; Wells M; Guerrero M; Asara JM; Libermann TA; Afdhal NH
    Clin Cancer Res; 2008 Jan; 14(2):470-7. PubMed ID: 18223221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
    Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
    J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarker discovery for early detection of hepatocellular carcinoma in hepatitis C-infected patients.
    Mustafa MG; Petersen JR; Ju H; Cicalese L; Snyder N; Haidacher SJ; Denner L; Elferink C
    Mol Cell Proteomics; 2013 Dec; 12(12):3640-52. PubMed ID: 24008390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of hepatocellular carcinoma using glycomic analysis.
    Goldman R; Ressom HW; Varghese RS; Goldman L; Bascug G; Loffredo CA; Abdel-Hamid M; Gouda I; Ezzat S; Kyselova Z; Mechref Y; Novotny MV
    Clin Cancer Res; 2009 Mar; 15(5):1808-13. PubMed ID: 19223512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum lipidomic profiling as a useful tool for screening potential biomarkers of hepatitis B-related hepatocellular carcinoma by ultraperformance liquid chromatography-mass spectrometry.
    Passos-Castilho AM; Carvalho VM; Cardozo KH; Kikuchi L; Chagas AL; Gomes-Gouvêa MS; Malta F; de Seixas-Santos Nastri AC; Pinho JR; Carrilho FJ; Granato CF
    BMC Cancer; 2015 Dec; 15():985. PubMed ID: 26680993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis accuracy of serum Glypican-3 level in patients with hepatocellular carcinoma and liver cirrhosis: a meta-analysis.
    Liu JW; Zuo XL; Wang S
    Eur Rev Med Pharmacol Sci; 2015 Oct; 19(19):3655-73. PubMed ID: 26502856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SELDI-TOF MS proteinchip technology for screening of serum markers of HBV-induced hepatocellular carcinoma.
    Geng X; Wang F; Li YG; Zhu GP; Zhang WM
    J Exp Clin Cancer Res; 2007 Dec; 26(4):505-8. PubMed ID: 18365545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum Beta-2 Microglobulin: a Possible Marker for Disease Progression in Egyptian Patients with Chronic HCV Related Liver Diseases.
    Ouda SM; Khairy AM; Sorour AE; Mikhail MN
    Asian Pac J Cancer Prev; 2015; 16(17):7825-9. PubMed ID: 26625805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker.
    Chen L; Ho DW; Lee NP; Sun S; Lam B; Wong KF; Yi X; Lau GK; Ng EW; Poon TC; Lai PB; Cai Z; Peng J; Leng X; Poon RT; Luk JM
    Ann Surg Oncol; 2010 Sep; 17(9):2518-25. PubMed ID: 20354800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential Serum Markers for Monitoring the Progression of Hepatitis B Virus-Associated Chronic Hepatic Lesions to Liver Cirrhosis.
    Wu C; Liu L; Zhao P; Tang D; Yao D; Zhu L; Wang Z
    Gut Liver; 2015 Sep; 9(5):665-71. PubMed ID: 25963079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward the proteomic identification of biomarkers for the prediction of HBV related hepatocellular carcinoma.
    He QY; Zhu R; Lei T; Ng MY; Luk JM; Sham P; Lau GK; Chiu JF
    J Cell Biochem; 2008 Feb; 103(3):740-52. PubMed ID: 17557278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum peptidome patterns of hepatocellular carcinoma based on magnetic bead separation and mass spectrometry analysis.
    Ying X; Han SX; Wang JL; Zhou X; Jin GH; Jin L; Wang H; Wu L; Zhang J; Zhu Q
    Diagn Pathol; 2013 Aug; 8():130. PubMed ID: 23915185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach.
    Lee IN; Chen CH; Sheu JC; Lee HS; Huang GT; Chen DS; Yu CY; Wen CL; Lu FJ; Chow LP
    Proteomics; 2006 May; 6(9):2865-73. PubMed ID: 16586433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk and predictors of hepatocellular carcinoma for chronic hepatitis B patients with newly developed cirrhosis.
    Chien J; Liu J; Lee MH; Jen CL; Batrla-Utermann R; Lu SN; Wang LY; You SL; Yang HI; Chen CJ
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1971-1977. PubMed ID: 27118149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.